Tumor caveolae-targeted systemic therapy of breast cancer with antibody drug conjugates
使用抗体药物缀合物对乳腺癌进行肿瘤小窝靶向全身治疗
基本信息
- 批准号:10237875
- 负责人:
- 金额:$ 42.32万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-09-01 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:Active Biological TransportAnnexin A1AntibodiesAntibody-drug conjugatesAntineoplastic AgentsBloodBlood CirculationBlood VesselsBreast Cancer ModelBreast Cancer TreatmentBreast Cancer therapyCause of DeathCaveolaeChemistryClinicalDataDevelopmentDiagnosisDiseaseDoseDrug Delivery SystemsDrug KineticsDrug TargetingERBB2 geneEndothelial CellsEndotheliumGlutathioneHumanIntravenousMalignant NeoplasmsMammary Gland ParenchymaMammary NeoplasmsMaximum Tolerated DoseMedicineMetastatic breast cancerModelingMolecularNatureNeoplasm MetastasisNeoplasms in Vascular TissueOperating SystemOrganPathway interactionsPatient-derived xenograft models of breast cancerPatientsPenetrationPharmaceutical PreparationsPhaseProductionPublishingPumpRattusRegimenRodentSafetySeriesSiteSolid NeoplasmSpecificitySpeedSurfaceSystemSystemic TherapyTherapeuticTherapeutic AgentsTherapeutic StudiesTimeTissuesToxic effectTranslationsTreatment EfficacyTumor TissueValidationVascular Endothelial CellWomanbasecancer diagnosischemotherapyclinical applicationclinical translationclinically relevantefficacy evaluationefficacy validationexperimental studyhuman modelhumanized antibodyimmunoreactivityimprovedintravital microscopymalignant breast neoplasmneoplastic cellnovelnovel therapeuticspersonalized medicinescreeningtargeted treatmenttherapeutic evaluationtreatment responsetreatment strategytumorvascular endothelium permeability
项目摘要
Breast cancer is the most commonly diagnosed cancer in women and is a second leading cause of death
among woman. Despite the significant progress in molecular understanding and personalized therapies of
breast cancer, this disease in progressed metastatic stage remains incurable and treatment options available
to patients provide only modest survival benefit. Efficacy of existing systemic chemotherapy is limited in
delivery, access and penetration into solid tumors, as well as by toxicity to patients. Thus, to develop more
effective and safer therapies of breast cancer, it is necessary to implement an efficient targeted drug delivery
system. Caveolae at the surface of tumor endothelial cells act as a transendothelial transport system that
actively pumps targeted antibodies from the blood circulation into the tumor tissue. Our findings support that
targeting caveolae provides a platform for rapid pumping of targeted antibodies with attached cargo specifically
into breast tumors at concentrations greatly exceeding maximum levels in the blood. Using these recent
findings, we intend to target antibody drug conjugates (ADC) of DM1 maytansinoid, one of the most potent
anticancer drugs to target truncated form of Annexin A1 in tumor endothelial caveolae in order to deliver this
powerful therapeutic effectively inside of breast tumors. We have demonstrated that AnnA1 is expressed in the
vasculature and caveolae of human tumors. Recently, we have generated humanized antibody against AnnA1
(hAnnA1) and our preliminary experiments demonstrate strong therapeutic response of breast cancer to
hAnnA1 conjugated to DM1 (hAnnA1-DM1 ADC). We hypothesize that by pumping targeted antibodies armed
with DM1 drug into breast tumors, caveolae can rapidly and specifically accumulate this therapeutic agent
inside tumors, leading to tumor destruction with significantly reduced toxicity. We propose these Specific Aims:
Aim 1. To generate and characterize ADCs. We will prepare series of conjugates with DM1 drug covalently
attached to hAnnA1 antibody using non-cleavable and cleavable linkers. Based on the screening in Aim2, we
will generate THIOMAB hAnnA1 with select linker chemistry.
Aim 2. Screening for optimal linker chemistry, production, validation and pharmacokinetic analysis of
tumor vascular caveolae-targeted DM1 THIOMAB ADC in rodent tumor model of breast cancer. These
studies will enable implementing optimal linker chemistry to develop ADC with site-specific attachment of DM1.
Aim 3. Evaluation of therapeutic efficacy of the tumor vascular caveolae-targeted DM1 ADCs in
clinically-relevant models of breast cancer. Therapeutic studies in clinically-relevant orthotopic models of
breast cancer, including intravital microscopy model of human tumor spheroids engrafted into human breast
tissue, and patient-derived breast cancer xenografts, including triple-negative and HER2+ models, will provide
platform to evaluate novel hAnnA1-DM1 ADC therapy. The proposed project will help to establish framework
for clinical translation of tumor-caveolae targeted ADC for treatment of breast cancer.
乳腺癌是女性最常见的癌症,也是第二大死亡原因
在女人中。尽管在分子理解和个性化治疗方面取得了重大进展,
乳腺癌,这种疾病在进展转移阶段仍然无法治愈,治疗选择可用
对患者仅提供适度的生存益处。现有全身化疗的疗效有限,
递送、进入和渗透到实体肿瘤中,以及对患者的毒性。因此,要发展更多
为了更有效、更安全地治疗乳腺癌,有必要实施高效的靶向药物输送
系统肿瘤内皮细胞表面的小窝作为跨内皮转运系统,
主动将靶向抗体从血液循环泵入肿瘤组织。我们的研究结果支持,
靶向小窝提供了一个平台,
进入乳腺肿瘤的浓度大大超过血液中的最大水平。利用这些最近
研究结果,我们打算靶向DM 1美登木素生物碱的抗体药物缀合物(ADC),
抗癌药物靶向肿瘤内皮细胞小窝中截短形式的膜联蛋白A1,
在乳腺肿瘤内有效的治疗。我们已经证明,AnnA 1表达在
人肿瘤的脉管系统和小窝。最近,我们已经产生了针对AnnA 1的人源化抗体,
(hAnnA 1)和我们的初步实验表明,乳腺癌的强治疗反应,
与DM 1缀合的hAnnA 1(hAnnA 1-DM 1 ADC)。我们假设通过注射有针对性的抗体
随着DM 1药物进入乳腺肿瘤,小窝可以迅速和特异性地积累这种治疗剂
在肿瘤内,导致肿瘤破坏,毒性显著降低。我们提出这些具体目标:
目标1。生成ADC并对其进行表征。我们将制备一系列与DM 1药物共价结合的偶联物
使用不可切割和可切割接头连接至hAnnA 1抗体。基于目标2中的筛选,我们
将产生具有选择的连接体化学的THIOMAB hAnnA 1。
目标2.筛选最佳接头化学,生产,验证和药代动力学分析
肿瘤血管小窝靶向DM 1 THIOMAB ADC在啮齿动物乳腺癌肿瘤模型中的应用这些
研究将能够实现最佳的连接体化学反应,以开发具有DM 1位点特异性连接的ADC。
目标3。评估肿瘤血管小窝靶向DM 1 ADC在肿瘤患者中的治疗功效
乳腺癌的临床相关模型。临床相关原位模型中的治疗研究
乳腺癌,包括移植到人乳腺中的人肿瘤球状体的活体显微镜模型
组织和患者来源的乳腺癌异种移植物,包括三阴性和HER 2+模型,将提供
评估新型hAnnA 1-DM 1 ADC疗法的平台。拟议项目将有助于建立框架
用于肿瘤-小窝靶向ADC的临床转化以治疗乳腺癌。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Adrian Chrastina其他文献
Adrian Chrastina的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Adrian Chrastina', 18)}}的其他基金
Tumor caveolae-targeted systemic therapy of breast cancer with antibody drug conjugates
使用抗体药物缀合物对乳腺癌进行肿瘤小窝靶向全身治疗
- 批准号:
10693126 - 财政年份:2019
- 资助金额:
$ 42.32万 - 项目类别:
Tumor caveolae-targeted systemic therapy of breast cancer with antibody drug conjugates
使用抗体药物缀合物对乳腺癌进行肿瘤小窝靶向全身治疗
- 批准号:
10472546 - 财政年份:2019
- 资助金额:
$ 42.32万 - 项目类别:
相似国自然基金
靶向Annexin A1蛋白预防CAR-T细胞治疗后BCMA阴性多发性骨髓瘤复发的机制研究
- 批准号:82370201
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
Annexin A1通过IFN-γ通路正向调控PD-L1介导肺腺癌免疫逃逸的机制研究
- 批准号:82172716
- 批准年份:2021
- 资助金额:55 万元
- 项目类别:面上项目
外源性尿酸调控SP1-Annexin a1在大鼠肝性脑病中的保护作用及机制研究
- 批准号:82060128
- 批准年份:2020
- 资助金额:34 万元
- 项目类别:地区科学基金项目
Annexin A1 调控 Notch1/Smad2/p15 信号轴促进急性髓系白血病细胞增殖的机制研究
- 批准号:81770176
- 批准年份:2017
- 资助金额:55.0 万元
- 项目类别:面上项目
Annexin A1通过调控TGF-β 受体内吞促进人卵巢癌细胞增殖的机制研究
- 批准号:81672577
- 批准年份:2016
- 资助金额:57.0 万元
- 项目类别:面上项目
膜联蛋白Annexin A1与Annexin A7在脑出血后继发性脑损伤中的作用机制研究
- 批准号:81571115
- 批准年份:2015
- 资助金额:57.0 万元
- 项目类别:面上项目
Annexin A1对婴幼儿体外循环术后急性肺损伤的保护研究
- 批准号:81400309
- 批准年份:2014
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
哺乳动物雷帕霉素靶蛋白(mTOR)介导膜联蛋白A1(Annexin A1)调控衰老相关胰岛β细胞功能下降的研究
- 批准号:81300265
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
Annexin A1在头颈鳞癌EGF相关ERK/MAPK信号通路中的作用机制
- 批准号:81272979
- 批准年份:2012
- 资助金额:65.0 万元
- 项目类别:面上项目
Annexin A1表达下调/缺失在鼻咽癌放疗抵抗中的作用及其分子机制研究
- 批准号:81272959
- 批准年份:2012
- 资助金额:78.0 万元
- 项目类别:面上项目
相似海外基金
Novel mitochondrial protective properties of annexin A1
膜联蛋白 A1 的新型线粒体保护特性
- 批准号:
10343330 - 财政年份:2021
- 资助金额:
$ 42.32万 - 项目类别:
Study on the role of annexin A1 in the regulation of gonadotropin secretion from the pituitary gland
膜联蛋白A1对垂体促性腺激素分泌调节作用的研究
- 批准号:
21K05964 - 财政年份:2021
- 资助金额:
$ 42.32万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Novel mitochondrial protective properties of annexin A1
膜联蛋白 A1 的新型线粒体保护特性
- 批准号:
10661073 - 财政年份:2021
- 资助金额:
$ 42.32万 - 项目类别:
ANNEXIN-A1 MIMETICS: A NOVEL THERAPEUTIC APPROACH FOR TARGETING THE CARDIAC COMPLICATIONS OF DIABETES
ANNEXIN-A1 模拟物:一种针对糖尿病心脏并发症的新型治疗方法
- 批准号:
nhmrc : GNT1081770 - 财政年份:2015
- 资助金额:
$ 42.32万 - 项目类别:
Project Grants
ANNEXIN-A1 MIMETICS: A NOVEL THERAPEUTIC APPROACH FOR TARGETING THE CARDIAC COMPLICATIONS OF DIABETES
ANNEXIN-A1 模拟物:一种针对糖尿病心脏并发症的新型治疗方法
- 批准号:
nhmrc : 1081770 - 财政年份:2015
- 资助金额:
$ 42.32万 - 项目类别:
Project Grants
Role of the downstream mediator of glucocorticoids, annexin A1, in the repair process of acute kidney injury
糖皮质激素下游介质膜联蛋白A1在急性肾损伤修复过程中的作用
- 批准号:
252481273 - 财政年份:2014
- 资助金额:
$ 42.32万 - 项目类别:
Research Units
Annexin-A1 Agonists Rescue Cardiac Contractile Function After Myocardial Infarction
膜联蛋白 A1 激动剂可挽救心肌梗塞后的心脏收缩功能
- 批准号:
nhmrc : 1045140 - 财政年份:2013
- 资助金额:
$ 42.32万 - 项目类别:
Project Grants
Targeted drug delivery to tumor vasculature by annexin A1 binding peptide
通过膜联蛋白 A1 结合肽将药物靶向递送至肿瘤脉管系统
- 批准号:
23791737 - 财政年份:2011
- 资助金额:
$ 42.32万 - 项目类别:
Grant-in-Aid for Young Scientists (B)